Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (NASDAQ: APYX) is a surgical aesthetics and advanced energy technology company whose news flow centers on its Helium Plasma Platform Technology products, including Renuvion, the AYON Body Contouring System, and J-Plasma. Company press releases focus on developments in the cosmetic surgery market, the hospital surgical market, and OEM relationships with other medical device manufacturers.
Investors and observers following APYX news will see regular updates on financial performance, such as quarterly and annual revenue results, preliminary unaudited revenue ranges, and segment-level trends in Surgical Aesthetics and OEM revenue. The company also issues guidance updates and discusses factors influencing its revenue mix, including the commercial rollout of AYON and demand for single-use handpieces and generators.
Another key category of Apyx Medical news involves product and regulatory milestones. Recent announcements describe FDA 510(k) clearances and submissions related to the AYON Body Contouring System, as well as international regulatory approvals like the Ministry of Food and Drug Safety clearance in South Korea for the Apyx One console and single-use handpieces. These items highlight how the company is expanding the indications and geographic reach of its platforms.
APYX news also covers capital markets and corporate actions, including proposed and completed public offerings of common stock under an effective Form S-3 shelf registration statement, as reported in 8-K filings and related press releases. Additional items include notices of investor conference participation, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and information about annual stockholder meetings and governance matters.
This news page aggregates these disclosures so readers can review Apyx Medical’s earnings releases, product launch updates, regulatory submissions, financing transactions, and investor events in one place.
Apyx Medical Corporation (NASDAQ:APYX) announced that it will release its financial results for Q1 of fiscal year 2023 before the market opens on May 11th. A conference call will follow at 8:00 a.m. Eastern Time on the same day, allowing for a discussion of the results and a Q&A session. Interested callers can join by dialing 877-407-8289 (or 201-689-8341 internationally) with access code 13737575. A live webcast will also be available through the Company’s Investor Relations section. This financial update is anticipated to provide insights into Apyx Medical's performance in the advanced energy technology market, including its innovative products Renuvion and J-Plasma, which are designed for cosmetic and hospital surgical applications.
Summary not available.
Apyx Medical Corporation (NASDAQ:APYX) reported its Q4 and full year 2022 results, revealing a 25% decline in total revenue to $12.6 million for Q4, and a 8% decrease for the year to $44.5 million. Advanced Energy revenue dropped 30% year-over-year to $10.5 million in Q4, while OEM revenue increased 15%. The company experienced a net loss of $6.0 million for Q4, worsening from $2.0 million a year earlier, and a loss of $23.2 million for 2022. Looking ahead, Apyx anticipates 2023 revenue between $58.0 million and $61.0 million, indicating a potential growth of 30% to 37% year-over-year. Key developments included the launch of a new marketing campaign and a secured $35 million credit facility.
Apyx Medical Corporation (NASDAQ:APYX) has received 510(k) clearance from the U.S. FDA for its Renuvion APR Handpiece. This device is approved for delivering radiofrequency energy and/or helium plasma for soft tissue coagulation and contraction, specifically subcutaneous tissue. CEO Charlie Goodwin emphasized this clearance underscores Renuvion's safety and effectiveness. Apyx is currently seeking an additional indication for use following liposuction, which remains under FDA review. The company specializes in advanced energy technology, aiming to elevate patient outcomes in cosmetic and surgical markets.
Apyx Medical Corporation has secured a new five-year credit facility worth up to $35 million from MidCap Financial. This facility includes senior secured term loans of up to $25 million and a revolving credit line of up to $10 million. The agreement provides about $8 million in net proceeds at closing, expected cash tax refunds of at least $7.5 million, and aims to enhance financial flexibility and support strategic growth initiatives. The loan terms require meeting specific revenue thresholds by December 2023 and September 2024.
Apyx Medical Corporation (NASDAQ: APYX) announced it will release its financial results for Q4 and fiscal year 2022 before the market opens on March 16th. Management will hold a conference call at 8:00 a.m. ET that same day to discuss these results and answer questions. Interested parties can access the call by dialing 877-407-8289 (international: 201-689-8341) using access code 13736530. The call will also be available via a live webcast. Apyx Medical specializes in advanced energy technology, particularly in helium plasma products marketed as Renuvion and J-Plasma for cosmetic and surgical applications.
Apyx Medical Corporation (NASDAQ:APYX) announced that its Renuvion neck laxity procedure will be featured on 'The Balancing Act' talk show on Lifetime on February 13, 2023, at 7:30 am ET/PT. The segment will showcase a minimally invasive neck procedure performed by Dr. Charles J. Galanis, highlighting its effectiveness in reducing sagging skin. Renuvion is the only FDA-cleared product for addressing neck and chin skin laxity, offering patients minimal downtime and cost-effectiveness. The segment will also re-run on February 21, 2023, with additional broadcasts throughout the year.
Apyx Medical Corporation (NASDAQ:APYX) has submitted a 510(k) premarket notification to the U.S. FDA for its Renuvion APR Handpiece, aiming to expand its use for coagulating subcutaneous soft tissues after liposuction. Supported by a clinical study and extensive evidence, the submission indicates that no new risks are associated with Renuvion when used post-liposuction. CEO Charlie Goodwin expressed optimism about receiving the FDA clearance, which may alleviate existing limitations outlined in the Medical Device Safety Communication.
Apyx Medical Corporation (NASDAQ: APYX) has launched the Apyx One Console, an advanced energy system now available to U.S. medical professionals. This multi-functional generator integrates Renuvion technology with monopolar and bipolar energy capabilities. Key features include adaptive touch screens, cloud connectivity, and a four-year warranty. Designed in collaboration with leading physicians, the Apyx One Console aims to enhance user experience and provides an upgrade option for existing customers. This product reinforces Apyx's commitment to innovation in the cosmetic surgery market.
Apyx Medical Corporation (NASDAQ:APYX) reported preliminary revenue results for Q4 and full year 2022, revealing a total revenue range of $12.1 to $12.5 million for Q4, a decline of 28% to 26% year-over-year. For the full year, revenue ranged from $44.0 to $44.4 million, declining by 9% to 8% year-over-year. The Advanced Energy segment showed significant declines of 33% to 30% in Q4 and 15% to 14% for the full year, while OEM revenue grew 12% in Q4 and 37% for the year. Despite challenges, the company plans for over 35% growth in 2023 driven by regulatory objectives.